179 results on '"Yi, John S."'
Search Results
2. Immune dysregulation in chronic inflammatory demyelinating polyneuropathy
3. Opportunities, barriers, and recommendations in down syndrome research
4. Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.
5. Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease
6. C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates
7. Immune cell profiles in synovial fluid after anterior cruciate ligament and meniscus injuries
8. Abstract 6674: Single-dose trilaciclib monotherapy potentiates antitumor immunity in the neoadjuvant setting of triple-negative breast cancer by modulating the composition and effector function of peripheral immune cells
9. Abstract 703: Transient G1 cell cycle arrest with trilaciclib enhances the generation of polyfunctional CD4+ and CD8+ T cells
10. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
11. Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
12. Table S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
13. Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
14. Table S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
15. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
16. Successful AAV8 re‐administration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease
17. Abstract P3-06-03: Trilaciclib induces immune changes within the tumor microenvironment in early-stage triple-negative breast cancer
18. Development of high sustained IgG antibody titers against rhGAA in patients with infantile Pompe disease is associated with a shift toward Th2 immune activation
19. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer
20. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2
21. B cells in the pathophysiology of myasthenia gravis
22. Successful AAV8 readministration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
23. Abstract 4204: CDK4/6 inhibition mitigates chemotherapy-induced immunosuppression and enhances the efficacy of chemo- immunotherapy in small cell lung cancer models
24. Abstract 2543: Chronic stress promotes tumor-associated inflammation in high-grade serous ovarian cancer
25. A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection
26. Adaptive immune response to therapy in hmgcr autoantibody myopathy
27. Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation
28. Cellular changes in eculizumab early responders with generalized myasthenia gravis
29. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
30. Normative dataset for plasma cytokines in healthy human adults
31. Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
32. PROLONGED B-CELL DEPLETION IN MUSK MYASTHENIA GRAVIS FOLLOWING RITUXIMAB TREATMENT
33. Reduced plasmablast frequency is associated with seronegative myasthenia gravis
34. Degenerative joint changes following intra‐articular fracture are more severe in mice with T cell deficiency
35. Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis
36. Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis
37. Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling
38. T-cell exhaustion: characteristics, causes and conversion
39. Degenerative joint changes following intra‐articular fracture are more severe in mice with T cell deficiency.
40. Immune cell profiling in the joint following human and murine articular fracture.
41. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients
42. Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
43. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients
44. Reduced plasmablast frequency is associated with seronegative myasthenia gravis.
45. B cells in the pathophysiology of myasthenia gravis
46. IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade
47. Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
48. Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
49. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates
50. B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.